US › Healthcare

SAB Biotherapeutics Inc (SABS)

US · Healthcare · Biotechnology

$3.50+3.24%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-22.5M

EPS

$-0.28

EPS estimate

$-0.29

EPS came in at -0.28 against a street estimate of -0.29 — a beat of 3.4%.

Key statistics

Market cap

$311.2M

P/E

14.2

Forward P/E

0.0

P/B

1.48

Book value

$2.57

EPS (TTM)

$0.24

52-week high

$5.15

52-week low

$1.85

50-day MA

$3.72

200-day MA

$3.82

Beta

0.54

Analyst view

Analysts rate SAB Biotherapeutics Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $11.64.

Shareholding

Insiders

0.71%

Institutions

75.42%

Largest institutional holders

Fund	Stake
Caligan Partners LP	8.76%
Vivo Capital, LLC	8.02%
Perceptive Advisors LLC	7.07%
Adage Capital Partners Gp LLC	7.04%
COMMODORE CAPITAL LP	4.84%
RA Capital Management, LLC	4.84%
Balyasny Asset Management LLC	4.13%
Woodline Partners LP	3.13%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for SAB Biotherapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.